ChemPartner PharmaTechLtd（300149）株式概要Chempartner Pharmatech Co, Ltd.は、微小生態栄養学とヘルスケア事業を世界中で展開している。 詳細300149 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析過去5年間で収益は年間23.1%減少しました。 すべてのリスクチェックを見る300149 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW496,407 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG496,407 investors already sharing narrativesYour Fair ValueCN¥Current PriceCN¥8.66114.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-914m2b2016201920222025202620282031Revenue CN¥615.9mEarnings CN¥111.9mAdvancedSet Fair ValueView all narrativesChemPartner PharmaTech Co.,Ltd. 競合他社Shanghai Serum Bio-TechnologySymbol: SHSE:688163Market cap: CN¥4.5bKexing BiopharmSymbol: SHSE:688136Market cap: CN¥4.1bWuhan Hiteck Biological PharmaLtdSymbol: SZSE:300683Market cap: CN¥3.3bGetein BiotechSymbol: SHSE:603387Market cap: CN¥4.3b価格と性能株価の高値、安値、推移の概要ChemPartner PharmaTechLtd過去の株価現在の株価CN¥8.6652週高値CN¥15.2852週安値CN¥7.22ベータ0.761ヶ月の変化9.90%3ヶ月変化-25.28%1年変化-16.97%3年間の変化11.17%5年間の変化-42.27%IPOからの変化28.64%最新ニュースBuy Or Sell Opportunity • Jul 10Now 23% overvaluedOver the last 90 days, the stock has fallen 20% to CN¥8.95. The fair value is estimated to be CN¥7.27, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.2% over the last 3 years. Meanwhile, the company became loss making.お知らせ • Jun 30ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2026 Results on Aug 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2026 results on Aug 29, 2026Buy Or Sell Opportunity • Jun 23Now 27% overvaluedOver the last 90 days, the stock has fallen 6.5% to CN¥9.14. The fair value is estimated to be CN¥7.22, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.2% over the last 3 years. Meanwhile, the company became loss making.New Risk • Jun 11New major risk - Revenue and earnings growthEarnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.New Risk • May 05New major risk - Revenue and earnings growthEarnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).Reported Earnings • Apr 30Full year 2025 earnings released: EPS: CN¥0.03 (vs CN¥0.45 loss in FY 2024)Full year 2025 results: EPS: CN¥0.03 (up from CN¥0.45 loss in FY 2024). Revenue: CN¥1.13b (up 17% from FY 2024). Net income: CN¥13.4m (up CN¥239.9m from FY 2024). Profit margin: 1.2% (up from net loss in FY 2024). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year.最新情報をもっと見るRecent updatesBuy Or Sell Opportunity • Jul 10Now 23% overvaluedOver the last 90 days, the stock has fallen 20% to CN¥8.95. The fair value is estimated to be CN¥7.27, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.2% over the last 3 years. Meanwhile, the company became loss making.お知らせ • Jun 30ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2026 Results on Aug 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2026 results on Aug 29, 2026Buy Or Sell Opportunity • Jun 23Now 27% overvaluedOver the last 90 days, the stock has fallen 6.5% to CN¥9.14. The fair value is estimated to be CN¥7.22, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.2% over the last 3 years. Meanwhile, the company became loss making.New Risk • Jun 11New major risk - Revenue and earnings growthEarnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.New Risk • May 05New major risk - Revenue and earnings growthEarnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).Reported Earnings • Apr 30Full year 2025 earnings released: EPS: CN¥0.03 (vs CN¥0.45 loss in FY 2024)Full year 2025 results: EPS: CN¥0.03 (up from CN¥0.45 loss in FY 2024). Revenue: CN¥1.13b (up 17% from FY 2024). Net income: CN¥13.4m (up CN¥239.9m from FY 2024). Profit margin: 1.2% (up from net loss in FY 2024). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year.お知らせ • Apr 29ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 28, 2026ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 28, 2026, at 13:30 China Standard Time. Location: Building A, No. 2829, Jinke Road, Zhangjiang Hi-tech Park, Pudong New Area, Shanghai ChinaNew Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 36% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.6% average weekly change).お知らせ • Mar 31ChemPartner PharmaTech Co.,Ltd. to Report Q1, 2026 Results on Apr 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026お知らせ • Dec 31ChemPartner PharmaTech Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026Reported Earnings • Oct 30Third quarter 2025 earnings released: CN¥0.036 loss per share (vs CN¥0.002 profit in 3Q 2024)Third quarter 2025 results: CN¥0.036 loss per share (down from CN¥0.002 profit in 3Q 2024). Revenue: CN¥283.1m (up 12% from 3Q 2024). Net loss: CN¥18.3m (down CN¥19.5m from profit in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.お知らせ • Sep 30ChemPartner PharmaTech Co.,Ltd. to Report Q3, 2025 Results on Oct 30, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025お知らせ • Jul 02ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2025 Results on Aug 29, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2025 results on Aug 29, 2025お知らせ • May 22Jiangmen Ruilian Pharmaceutical Investment Co., Ltd. completed the acquisition of 5.35% stake in ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) from Yunnan Baben Health Industry Co., Ltd.Jiangmen Ruilian Pharmaceutical Investment Co., Ltd. agreed to acquire 5.35% stake in ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) from Yunnan Baben Health Industry Co., Ltd. for approximately CNY 130 million on March 31, 2025. The consideration consist of CNY 5.064 per ChemPartner PharmaTech Co.,Ltd. share. Jiangmen Ruilian Pharmaceutical Investment Co., Ltd. completed the acquisition of 5.35% stake in ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) from Yunnan Baben Health Industry Co., Ltd. on May 20, 2025.Reported Earnings • Apr 29Full year 2024 earnings released: CN¥0.45 loss per share (vs CN¥1.82 loss in FY 2023)Full year 2024 results: CN¥0.45 loss per share (improved from CN¥1.82 loss in FY 2023). Revenue: CN¥970.2m (down 15% from FY 2023). Net loss: CN¥226.5m (loss narrowed 75% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.お知らせ • Apr 29ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 29, 2025ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 29, 2025, at 14:00 China Standard Time.お知らせ • Mar 31ChemPartner PharmaTech Co.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025お知らせ • Dec 31ChemPartner PharmaTech Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025分析記事 • Dec 10Is ChemPartner PharmaTechLtd (SZSE:300149) Using Debt In A Risky Way?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...お知らせ • Nov 16ChemPartner PharmaTech Co.,Ltd. Approves the Election of DirectorsChemPartner PharmaTech Co.,Ltd. held its 2nd Extraordinary General Meeting of 2024 on 14 November 2024, during which the following proposal(s) was/were approved the election of Chen Wanglong as non-independent director and Zhang Xuemei as independent director.分析記事 • Sep 30ChemPartner PharmaTech Co.,Ltd.'s (SZSE:300149) Price Is Right But Growth Is Lacking After Shares Rocket 51%ChemPartner PharmaTech Co.,Ltd. ( SZSE:300149 ) shares have continued their recent momentum with a 51% gain in the last...お知らせ • Sep 30ChemPartner PharmaTech Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024ChemPartner PharmaTech Co.,Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024Reported Earnings • Aug 30Second quarter 2024 earnings released: CN¥0.076 loss per share (vs CN¥0.011 profit in 2Q 2023)Second quarter 2024 results: CN¥0.076 loss per share (down from CN¥0.011 profit in 2Q 2023). Revenue: CN¥230.6m (down 20% from 2Q 2023). Net loss: CN¥37.4m (down CN¥44.2m from profit in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 39 percentage points per year, which is a significant difference in performance.分析記事 • Aug 04Improved Revenues Required Before ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) Stock's 29% Jump Looks JustifiedThose holding ChemPartner PharmaTech Co.,Ltd. ( SZSE:300149 ) shares would be relieved that the share price has...お知らせ • Jun 29ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2024 Results on Aug 30, 2024ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2024 results on Aug 30, 2024お知らせ • Apr 28Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024, at 14:00 China Standard Time. Location: Building A, No. 2829, Jinke Road, Zhangjiang Hi-tech Park, Pudong New Area, Shanghai China Agenda: To consider 2023 work report of the board of directors; to consider 2023 annual accounts report; to consider 2023 annual report and its summary; to consider 2023 profit distribution plan; to consider Application for comprehensive credit line to banks and other financial institutions and provision of guarantee; to consider Shareholder return plan for the next three years from 2024 to 2026; to consider Authorization to the board to handle matters regarding the share offering to specific parties via a simplified procedure; to consider Change of the Company's business scope and amendments to the Company's articles of association; to consider 2023 work report of the supervisory committee; and to consider other business matters.Reported Earnings • Apr 27First quarter 2024 earnings released: CN¥0.051 loss per share (vs CN¥0.057 loss in 1Q 2023)First quarter 2024 results: CN¥0.051 loss per share (improved from CN¥0.057 loss in 1Q 2023). Revenue: CN¥234.6m (down 13% from 1Q 2023). Net loss: CN¥25.5m (loss narrowed 11% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 35 percentage points per year, which is a significant difference in performance.New Risk • Apr 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).お知らせ • Mar 30Chempartner Pharmatech Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024Chempartner Pharmatech Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024分析記事 • Mar 08Chempartner Pharmatech Co., Ltd.'s (SZSE:300149) Share Price Boosted 29% But Its Business Prospects Need A Lift TooChempartner Pharmatech Co., Ltd. ( SZSE:300149 ) shareholders are no doubt pleased to see that the share price has...お知らせ • Dec 30Chempartner Pharmatech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024Chempartner Pharmatech Co., Ltd. announced that they will report fiscal year 2023 results on Apr 26, 2024Reported Earnings • Oct 25Third quarter 2023 earnings released: CN¥0.048 loss per share (vs CN¥0.13 profit in 3Q 2022)Third quarter 2023 results: CN¥0.048 loss per share (down from CN¥0.13 profit in 3Q 2022). Revenue: CN¥288.7m (down 16% from 3Q 2022). Net loss: CN¥19.4m (down 129% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 29Second quarter 2023 earnings released: EPS: CN¥0.011 (vs CN¥1.90 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.011 (down from CN¥1.90 in 2Q 2022). Revenue: CN¥288.8m (down 3.9% from 2Q 2022). Net income: CN¥6.79m (down 99% from 2Q 2022). Profit margin: 2.4% (down from 315% in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.Valuation Update With 7 Day Price Move • Aug 23Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to CN¥7.25, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 36x in the Biotechs industry in China. Total loss to shareholders of 65% over the past three years.New Risk • Aug 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Large one-off items impacting financial results.Valuation Update With 7 Day Price Move • Aug 03Investor sentiment improves as stock rises 19%After last week's 19% share price gain to CN¥9.47, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 40x in the Biotechs industry in China. Total loss to shareholders of 58% over the past three years.Reported Earnings • Apr 28First quarter 2023 earnings released: CN¥0.057 loss per share (vs CN¥0.019 profit in 1Q 2022)First quarter 2023 results: CN¥0.057 loss per share (down from CN¥0.019 profit in 1Q 2022). Revenue: CN¥268.7m (down 31% from 1Q 2022). Net loss: CN¥28.6m (down 402% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Apr 27Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CN¥8.47, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 39x in the Biotechs industry in China. Total loss to shareholders of 23% over the past three years.Board Change • Nov 16Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Supervisor Jiahui Qi is the most experienced director on the board, commencing their role in 2018. Independent Director Ji Guo Zhang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Valuation Update With 7 Day Price Move • Nov 11Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥12.23, the stock trades at a trailing P/E ratio of 10x. Average trailing P/E is 39x in the Biotechs industry in China. Total loss to shareholders of 13% over the past three years.Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.021 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.13 (up from CN¥0.021 in 3Q 2021). Revenue: CN¥345.3m (down 17% from 3Q 2021). Net income: CN¥66.8m (up CN¥57.1m from 3Q 2021). Profit margin: 19% (up from 2.3% in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 01Second quarter 2022 earnings released: EPS: CN¥1.90 (vs CN¥0.007 in 2Q 2021)Second quarter 2022 results: EPS: CN¥1.90 (up from CN¥0.007 in 2Q 2021). Revenue: CN¥300.6m (down 34% from 2Q 2021). Net income: CN¥947.1m (up CN¥943.6m from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.お知らせ • Jun 11Tate & Lyle Investments Limited completed the acquisition of Quantum Hi-Tech (Guangdong) Biological Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149).Tate & Lyle Investments Limited agreed to acquire Quantum Hi-Tech (Guangdong) Biological Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149) for CNY 1500 million on March 30, 2022. Chempartner Pharmatech's board of directors approved the transaction. As November 30, 2022, Quantum Hi-Tech (Guangdong) Biological reported the Total assets of CNY 268,686,400 and Net assets of CNY 172,838,300. The management team of Quantum will join Tate & Lyle at completion. The transaction is subject to approval by the shareholders of ChemPartner. The acquisition is expected to be accretive to revenue growth and EBITDA margin for Tate & Lyle in the first year of ownership. Andrew Boyd and Chuan Sun of Morrison & Foerster (UK) LLP acted as legal advisor to Tate and Lyle. Tate & Lyle Investments Limited completed the acquisition of Quantum Hi-Tech (Guangdong) Biological Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149) on June 9, 2022.お知らせ • May 10Chempartner Pharmatech Co., Ltd. announced that it expects to receive CNY 300 million in fundingChempartner Pharmatech Co., Ltd. announced a private placement of A shares for gross proceeds of not more than CNY 300,000,000 on May 8, 2022. The issue price shall not be lower than 80% of the average stock trading price of the 20 trading days prior to the pricing benchmark date. The transaction will include participation from not more than 35 investors. The shares issued will be subject to restriction period of 6 months from closing. The transaction has been approved at the 18th meeting of 5th session of board of directors, subject to 2021 annual general meeting.お知らせ • May 07Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 23, 2022Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 23, 2022, at 14:00 China Standard Time. Agenda: To consider 2021 work report of the board of directors; to consider 2021 annual accounts; to consider 2021 annual report and its summary; to consider 2021 profit distribution plan; to consider Provision for goodwill impairment; to consider 2022 estimated continuing connected transactions; to consider an application for comprehensive credit line to banks and other financial institutions; to consider the change of the Company's domicile and amendments to the Company's articles of association; and to consider 2021 work report of the supervisory committee.Reported Earnings • May 02First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: EPS: CN¥0.019 (up from CN¥0.003 in 1Q 2021). Revenue: CN¥386.3m (flat on 1Q 2021). Net income: CN¥9.47m (up 480% from 1Q 2021). Profit margin: 2.5% (up from 0.4% in 1Q 2021). Revenue missed analyst estimates by 5.3%. Earnings per share (EPS) also missed analyst estimates by 18%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.お知らせ • May 02Chempartner Pharmatech Co., Ltd. to Report Fiscal Year 2021 Results on Apr 30, 2022Chempartner Pharmatech Co., Ltd. announced that they will report fiscal year 2021 results on Apr 30, 2022Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Member of the Supervisory Board Hai Zhang was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Jan 24Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to CN¥13.46, the stock trades at a trailing P/E ratio of 77.9x. Average trailing P/E is 46x in the Biotechs industry in China. Total loss to shareholders of 12% over the past three years.Reported Earnings • Nov 01Third quarter 2021 earnings released: EPS CN¥0.021 (vs CN¥0.085 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥416.1m (up 4.2% from 3Q 2020). Net income: CN¥9.70m (down 77% from 3Q 2020). Profit margin: 2.3% (down from 11% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 30Second quarter 2021 earnings released: EPS CN¥0.007 (vs CN¥0.11 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥455.7m (up 16% from 2Q 2020). Net income: CN¥3.51m (down 94% from 2Q 2020). Profit margin: 0.8% (down from 14% in 2Q 2020). Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 5% per year.Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improved over the past weekAfter last week's 20% share price gain to CN¥20.55, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 44x in the Biotechs industry in China. Total returns to shareholders of 25% over the past three years.お知らせ • May 27Chempartner Pharmatech Co., Ltd. Announces Final Cash Dividend for 2020, Payable on 1 June 2021Chempartner Pharmatech Co., Ltd. announced final cash dividend CNY0.70203600 per ten shares (tax included) for 2020, payable on 1 June 2021. The record date is 31 May 2021 and the ex-date is 1 June 2021.お知らせ • May 22Chempartner Pharmatech Co., Ltd. Approves Cash Dividend for the Year 2020Chempartner Pharmatech Co., Ltd. at its annual general meeting held on May 20, 2021, approved cash dividend per ten shares (tax included) of CNY 0.70000000 for the year 2020.Valuation Update With 7 Day Price Move • May 14Investor sentiment improved over the past weekAfter last week's 19% share price gain to CN¥16.39, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 45x in the Biotechs industry in China. Total loss to shareholders of 26% over the past three years.お知らせ • Apr 29Chempartner Pharmatech Co., Ltd. Announces the Profit Distribution Proposal for 2020Chempartner Pharmatech Co., Ltd. announced the profit distribution proposal for 2020. The company announced Cash dividend/10 shares (tax included) of CNY 0.70000000.Reported Earnings • Apr 29First quarter 2021 earnings released: EPS CN¥0.003 (vs CN¥0.028 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥389.7m (up 40% from 1Q 2020). Net income: CN¥1.63m (up CN¥15.8m from 1Q 2020). Profit margin: 0.4% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Mar 15New 90-day low: CN¥12.64The company is down 29% from a price of CN¥17.76 on 15 December 2020. Underperformed the Chinese market, which is flat over the last 90 days. Lagged the Biotechs industry, which is down 2.0% over the same period.Is New 90 Day High Low • Jan 28New 90-day low: CN¥12.66The company is down 36% from its price of CN¥19.93 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.53 per share.Valuation Update With 7 Day Price Move • Dec 24Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to CN¥14.46, the stock is trading at a trailing P/E ratio of 51.2x, down from the previous P/E ratio of 62.9x. This compares to an average P/E of 63x in the Biotechs industry in China. Total returns to shareholders over the past year are 8.9%.Is New 90 Day High Low • Dec 24New 90-day low: CN¥14.46The company is down 31% from its price of CN¥20.99 on 25 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.55 per share.Is New 90 Day High Low • Nov 11New 90-day low: CN¥18.29The company is down 4.0% from its price of CN¥19.06 on 13 August 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥13.16 per share.Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥141.1m, up 8.5% from the prior year. Total revenue was CN¥1.44b over the last 12 months, up 8.5% from the prior year.お知らせ • Aug 13Quantum Hi-Tech (China) Biological Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020Quantum Hi-Tech (China) Biological Co., Ltd. announced that they will report first half, 2020 results on Aug 28, 2020株主還元300149CN BiotechsCN 市場7D-1.4%-4.4%-5.6%1Y-17.0%-22.5%17.5%株主還元を見る業界別リターン: 300149過去 1 年間で-22.5 % の収益を上げたCN Biotechs業界を上回りました。リターン対市場: 300149は、過去 1 年間で17.5 % のリターンを上げたCN市場を下回りました。価格変動Is 300149's price volatile compared to industry and market?300149 volatility300149 Average Weekly Movement9.2%Biotechs Industry Average Movement6.5%Market Average Movement7.0%10% most volatile stocks in CN Market11.5%10% least volatile stocks in CN Market4.1%安定した株価: 300149 、 CN市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 300149の 週次ボラティリティ ( 9% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト20001,771Swee Lian Woowww.cppt.com.cnチェンパートナー・ファーマテック株式会社は、微量生態学的栄養学とヘルスケア事業を世界中で展開している。微小生態学的栄養・医療事業、医薬品研究開発サービス・生産アウトソーシング事業の2つのセグメントで事業を展開。プレバイオティクス製品の提供、マイクロエコロジー医療サービスの提供。大手・中堅製薬会社、バイオテクノロジー企業、科学研究機関向けに、総合的な化学医薬品研究開発および生物医薬品サービスを提供している。旧社名は量子高科技（中国）生物有限公司で、2020年9月にチェンパートナー・ファーマテック株式会社に社名変更した。Chempartner Pharmatech Co., Ltd.は2000年に設立され、中国の広州に本社を置いている。もっと見るChemPartner PharmaTech Co.,Ltd. 基礎のまとめChemPartner PharmaTechLtd の収益と売上を時価総額と比較するとどうか。300149 基礎統計学時価総額CN¥4.31b収益（TTM）-CN¥11.39m売上高(TTM)CN¥1.14b3.8xP/Sレシオ-378.7xPER（株価収益率300149 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計300149 損益計算書（TTM）収益CN¥1.14b売上原価CN¥826.09m売上総利益CN¥314.06mその他の費用CN¥325.44m収益-CN¥11.39m直近の収益報告Mar 31, 2026次回決算日Aug 29, 2026一株当たり利益（EPS）-0.023グロス・マージン27.55%純利益率-1.00%有利子負債／自己資本比率7.3%300149 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/14 18:15終値2026/07/14 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ChemPartner PharmaTech Co.,Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関null nullCMB International Securities LimitedXiao Bao LiuEverbright Securities Co. Ltd.Yun ZHANGHuatai Research
Buy Or Sell Opportunity • Jul 10Now 23% overvaluedOver the last 90 days, the stock has fallen 20% to CN¥8.95. The fair value is estimated to be CN¥7.27, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.2% over the last 3 years. Meanwhile, the company became loss making.
お知らせ • Jun 30ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2026 Results on Aug 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2026 results on Aug 29, 2026
Buy Or Sell Opportunity • Jun 23Now 27% overvaluedOver the last 90 days, the stock has fallen 6.5% to CN¥9.14. The fair value is estimated to be CN¥7.22, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.2% over the last 3 years. Meanwhile, the company became loss making.
New Risk • Jun 11New major risk - Revenue and earnings growthEarnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
New Risk • May 05New major risk - Revenue and earnings growthEarnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).
Reported Earnings • Apr 30Full year 2025 earnings released: EPS: CN¥0.03 (vs CN¥0.45 loss in FY 2024)Full year 2025 results: EPS: CN¥0.03 (up from CN¥0.45 loss in FY 2024). Revenue: CN¥1.13b (up 17% from FY 2024). Net income: CN¥13.4m (up CN¥239.9m from FY 2024). Profit margin: 1.2% (up from net loss in FY 2024). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year.
Buy Or Sell Opportunity • Jul 10Now 23% overvaluedOver the last 90 days, the stock has fallen 20% to CN¥8.95. The fair value is estimated to be CN¥7.27, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.2% over the last 3 years. Meanwhile, the company became loss making.
お知らせ • Jun 30ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2026 Results on Aug 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2026 results on Aug 29, 2026
Buy Or Sell Opportunity • Jun 23Now 27% overvaluedOver the last 90 days, the stock has fallen 6.5% to CN¥9.14. The fair value is estimated to be CN¥7.22, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.2% over the last 3 years. Meanwhile, the company became loss making.
New Risk • Jun 11New major risk - Revenue and earnings growthEarnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
New Risk • May 05New major risk - Revenue and earnings growthEarnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).
Reported Earnings • Apr 30Full year 2025 earnings released: EPS: CN¥0.03 (vs CN¥0.45 loss in FY 2024)Full year 2025 results: EPS: CN¥0.03 (up from CN¥0.45 loss in FY 2024). Revenue: CN¥1.13b (up 17% from FY 2024). Net income: CN¥13.4m (up CN¥239.9m from FY 2024). Profit margin: 1.2% (up from net loss in FY 2024). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year.
お知らせ • Apr 29ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 28, 2026ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 28, 2026, at 13:30 China Standard Time. Location: Building A, No. 2829, Jinke Road, Zhangjiang Hi-tech Park, Pudong New Area, Shanghai China
New Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 36% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.6% average weekly change).
お知らせ • Mar 31ChemPartner PharmaTech Co.,Ltd. to Report Q1, 2026 Results on Apr 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026
お知らせ • Dec 31ChemPartner PharmaTech Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026ChemPartner PharmaTech Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026
Reported Earnings • Oct 30Third quarter 2025 earnings released: CN¥0.036 loss per share (vs CN¥0.002 profit in 3Q 2024)Third quarter 2025 results: CN¥0.036 loss per share (down from CN¥0.002 profit in 3Q 2024). Revenue: CN¥283.1m (up 12% from 3Q 2024). Net loss: CN¥18.3m (down CN¥19.5m from profit in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
お知らせ • Sep 30ChemPartner PharmaTech Co.,Ltd. to Report Q3, 2025 Results on Oct 30, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025
お知らせ • Jul 02ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2025 Results on Aug 29, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2025 results on Aug 29, 2025
お知らせ • May 22Jiangmen Ruilian Pharmaceutical Investment Co., Ltd. completed the acquisition of 5.35% stake in ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) from Yunnan Baben Health Industry Co., Ltd.Jiangmen Ruilian Pharmaceutical Investment Co., Ltd. agreed to acquire 5.35% stake in ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) from Yunnan Baben Health Industry Co., Ltd. for approximately CNY 130 million on March 31, 2025. The consideration consist of CNY 5.064 per ChemPartner PharmaTech Co.,Ltd. share. Jiangmen Ruilian Pharmaceutical Investment Co., Ltd. completed the acquisition of 5.35% stake in ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) from Yunnan Baben Health Industry Co., Ltd. on May 20, 2025.
Reported Earnings • Apr 29Full year 2024 earnings released: CN¥0.45 loss per share (vs CN¥1.82 loss in FY 2023)Full year 2024 results: CN¥0.45 loss per share (improved from CN¥1.82 loss in FY 2023). Revenue: CN¥970.2m (down 15% from FY 2023). Net loss: CN¥226.5m (loss narrowed 75% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 29ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 29, 2025ChemPartner PharmaTech Co.,Ltd., Annual General Meeting, May 29, 2025, at 14:00 China Standard Time.
お知らせ • Mar 31ChemPartner PharmaTech Co.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025
お知らせ • Dec 31ChemPartner PharmaTech Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025ChemPartner PharmaTech Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025
分析記事 • Dec 10Is ChemPartner PharmaTechLtd (SZSE:300149) Using Debt In A Risky Way?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
お知らせ • Nov 16ChemPartner PharmaTech Co.,Ltd. Approves the Election of DirectorsChemPartner PharmaTech Co.,Ltd. held its 2nd Extraordinary General Meeting of 2024 on 14 November 2024, during which the following proposal(s) was/were approved the election of Chen Wanglong as non-independent director and Zhang Xuemei as independent director.
分析記事 • Sep 30ChemPartner PharmaTech Co.,Ltd.'s (SZSE:300149) Price Is Right But Growth Is Lacking After Shares Rocket 51%ChemPartner PharmaTech Co.,Ltd. ( SZSE:300149 ) shares have continued their recent momentum with a 51% gain in the last...
お知らせ • Sep 30ChemPartner PharmaTech Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024ChemPartner PharmaTech Co.,Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024
Reported Earnings • Aug 30Second quarter 2024 earnings released: CN¥0.076 loss per share (vs CN¥0.011 profit in 2Q 2023)Second quarter 2024 results: CN¥0.076 loss per share (down from CN¥0.011 profit in 2Q 2023). Revenue: CN¥230.6m (down 20% from 2Q 2023). Net loss: CN¥37.4m (down CN¥44.2m from profit in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 39 percentage points per year, which is a significant difference in performance.
分析記事 • Aug 04Improved Revenues Required Before ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) Stock's 29% Jump Looks JustifiedThose holding ChemPartner PharmaTech Co.,Ltd. ( SZSE:300149 ) shares would be relieved that the share price has...
お知らせ • Jun 29ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2024 Results on Aug 30, 2024ChemPartner PharmaTech Co.,Ltd. announced that they will report first half, 2024 results on Aug 30, 2024
お知らせ • Apr 28Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024, at 14:00 China Standard Time. Location: Building A, No. 2829, Jinke Road, Zhangjiang Hi-tech Park, Pudong New Area, Shanghai China Agenda: To consider 2023 work report of the board of directors; to consider 2023 annual accounts report; to consider 2023 annual report and its summary; to consider 2023 profit distribution plan; to consider Application for comprehensive credit line to banks and other financial institutions and provision of guarantee; to consider Shareholder return plan for the next three years from 2024 to 2026; to consider Authorization to the board to handle matters regarding the share offering to specific parties via a simplified procedure; to consider Change of the Company's business scope and amendments to the Company's articles of association; to consider 2023 work report of the supervisory committee; and to consider other business matters.
Reported Earnings • Apr 27First quarter 2024 earnings released: CN¥0.051 loss per share (vs CN¥0.057 loss in 1Q 2023)First quarter 2024 results: CN¥0.051 loss per share (improved from CN¥0.057 loss in 1Q 2023). Revenue: CN¥234.6m (down 13% from 1Q 2023). Net loss: CN¥25.5m (loss narrowed 11% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 35 percentage points per year, which is a significant difference in performance.
New Risk • Apr 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).
お知らせ • Mar 30Chempartner Pharmatech Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024Chempartner Pharmatech Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024
分析記事 • Mar 08Chempartner Pharmatech Co., Ltd.'s (SZSE:300149) Share Price Boosted 29% But Its Business Prospects Need A Lift TooChempartner Pharmatech Co., Ltd. ( SZSE:300149 ) shareholders are no doubt pleased to see that the share price has...
お知らせ • Dec 30Chempartner Pharmatech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024Chempartner Pharmatech Co., Ltd. announced that they will report fiscal year 2023 results on Apr 26, 2024
Reported Earnings • Oct 25Third quarter 2023 earnings released: CN¥0.048 loss per share (vs CN¥0.13 profit in 3Q 2022)Third quarter 2023 results: CN¥0.048 loss per share (down from CN¥0.13 profit in 3Q 2022). Revenue: CN¥288.7m (down 16% from 3Q 2022). Net loss: CN¥19.4m (down 129% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 29Second quarter 2023 earnings released: EPS: CN¥0.011 (vs CN¥1.90 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.011 (down from CN¥1.90 in 2Q 2022). Revenue: CN¥288.8m (down 3.9% from 2Q 2022). Net income: CN¥6.79m (down 99% from 2Q 2022). Profit margin: 2.4% (down from 315% in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.
Valuation Update With 7 Day Price Move • Aug 23Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to CN¥7.25, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 36x in the Biotechs industry in China. Total loss to shareholders of 65% over the past three years.
New Risk • Aug 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Large one-off items impacting financial results.
Valuation Update With 7 Day Price Move • Aug 03Investor sentiment improves as stock rises 19%After last week's 19% share price gain to CN¥9.47, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 40x in the Biotechs industry in China. Total loss to shareholders of 58% over the past three years.
Reported Earnings • Apr 28First quarter 2023 earnings released: CN¥0.057 loss per share (vs CN¥0.019 profit in 1Q 2022)First quarter 2023 results: CN¥0.057 loss per share (down from CN¥0.019 profit in 1Q 2022). Revenue: CN¥268.7m (down 31% from 1Q 2022). Net loss: CN¥28.6m (down 402% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Apr 27Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CN¥8.47, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 39x in the Biotechs industry in China. Total loss to shareholders of 23% over the past three years.
Board Change • Nov 16Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Supervisor Jiahui Qi is the most experienced director on the board, commencing their role in 2018. Independent Director Ji Guo Zhang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Valuation Update With 7 Day Price Move • Nov 11Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥12.23, the stock trades at a trailing P/E ratio of 10x. Average trailing P/E is 39x in the Biotechs industry in China. Total loss to shareholders of 13% over the past three years.
Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.021 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.13 (up from CN¥0.021 in 3Q 2021). Revenue: CN¥345.3m (down 17% from 3Q 2021). Net income: CN¥66.8m (up CN¥57.1m from 3Q 2021). Profit margin: 19% (up from 2.3% in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 01Second quarter 2022 earnings released: EPS: CN¥1.90 (vs CN¥0.007 in 2Q 2021)Second quarter 2022 results: EPS: CN¥1.90 (up from CN¥0.007 in 2Q 2021). Revenue: CN¥300.6m (down 34% from 2Q 2021). Net income: CN¥947.1m (up CN¥943.6m from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
お知らせ • Jun 11Tate & Lyle Investments Limited completed the acquisition of Quantum Hi-Tech (Guangdong) Biological Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149).Tate & Lyle Investments Limited agreed to acquire Quantum Hi-Tech (Guangdong) Biological Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149) for CNY 1500 million on March 30, 2022. Chempartner Pharmatech's board of directors approved the transaction. As November 30, 2022, Quantum Hi-Tech (Guangdong) Biological reported the Total assets of CNY 268,686,400 and Net assets of CNY 172,838,300. The management team of Quantum will join Tate & Lyle at completion. The transaction is subject to approval by the shareholders of ChemPartner. The acquisition is expected to be accretive to revenue growth and EBITDA margin for Tate & Lyle in the first year of ownership. Andrew Boyd and Chuan Sun of Morrison & Foerster (UK) LLP acted as legal advisor to Tate and Lyle. Tate & Lyle Investments Limited completed the acquisition of Quantum Hi-Tech (Guangdong) Biological Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149) on June 9, 2022.
お知らせ • May 10Chempartner Pharmatech Co., Ltd. announced that it expects to receive CNY 300 million in fundingChempartner Pharmatech Co., Ltd. announced a private placement of A shares for gross proceeds of not more than CNY 300,000,000 on May 8, 2022. The issue price shall not be lower than 80% of the average stock trading price of the 20 trading days prior to the pricing benchmark date. The transaction will include participation from not more than 35 investors. The shares issued will be subject to restriction period of 6 months from closing. The transaction has been approved at the 18th meeting of 5th session of board of directors, subject to 2021 annual general meeting.
お知らせ • May 07Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 23, 2022Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 23, 2022, at 14:00 China Standard Time. Agenda: To consider 2021 work report of the board of directors; to consider 2021 annual accounts; to consider 2021 annual report and its summary; to consider 2021 profit distribution plan; to consider Provision for goodwill impairment; to consider 2022 estimated continuing connected transactions; to consider an application for comprehensive credit line to banks and other financial institutions; to consider the change of the Company's domicile and amendments to the Company's articles of association; and to consider 2021 work report of the supervisory committee.
Reported Earnings • May 02First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: EPS: CN¥0.019 (up from CN¥0.003 in 1Q 2021). Revenue: CN¥386.3m (flat on 1Q 2021). Net income: CN¥9.47m (up 480% from 1Q 2021). Profit margin: 2.5% (up from 0.4% in 1Q 2021). Revenue missed analyst estimates by 5.3%. Earnings per share (EPS) also missed analyst estimates by 18%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.
お知らせ • May 02Chempartner Pharmatech Co., Ltd. to Report Fiscal Year 2021 Results on Apr 30, 2022Chempartner Pharmatech Co., Ltd. announced that they will report fiscal year 2021 results on Apr 30, 2022
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Member of the Supervisory Board Hai Zhang was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Jan 24Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to CN¥13.46, the stock trades at a trailing P/E ratio of 77.9x. Average trailing P/E is 46x in the Biotechs industry in China. Total loss to shareholders of 12% over the past three years.
Reported Earnings • Nov 01Third quarter 2021 earnings released: EPS CN¥0.021 (vs CN¥0.085 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥416.1m (up 4.2% from 3Q 2020). Net income: CN¥9.70m (down 77% from 3Q 2020). Profit margin: 2.3% (down from 11% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 30Second quarter 2021 earnings released: EPS CN¥0.007 (vs CN¥0.11 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥455.7m (up 16% from 2Q 2020). Net income: CN¥3.51m (down 94% from 2Q 2020). Profit margin: 0.8% (down from 14% in 2Q 2020). Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 5% per year.
Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improved over the past weekAfter last week's 20% share price gain to CN¥20.55, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 44x in the Biotechs industry in China. Total returns to shareholders of 25% over the past three years.
お知らせ • May 27Chempartner Pharmatech Co., Ltd. Announces Final Cash Dividend for 2020, Payable on 1 June 2021Chempartner Pharmatech Co., Ltd. announced final cash dividend CNY0.70203600 per ten shares (tax included) for 2020, payable on 1 June 2021. The record date is 31 May 2021 and the ex-date is 1 June 2021.
お知らせ • May 22Chempartner Pharmatech Co., Ltd. Approves Cash Dividend for the Year 2020Chempartner Pharmatech Co., Ltd. at its annual general meeting held on May 20, 2021, approved cash dividend per ten shares (tax included) of CNY 0.70000000 for the year 2020.
Valuation Update With 7 Day Price Move • May 14Investor sentiment improved over the past weekAfter last week's 19% share price gain to CN¥16.39, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 45x in the Biotechs industry in China. Total loss to shareholders of 26% over the past three years.
お知らせ • Apr 29Chempartner Pharmatech Co., Ltd. Announces the Profit Distribution Proposal for 2020Chempartner Pharmatech Co., Ltd. announced the profit distribution proposal for 2020. The company announced Cash dividend/10 shares (tax included) of CNY 0.70000000.
Reported Earnings • Apr 29First quarter 2021 earnings released: EPS CN¥0.003 (vs CN¥0.028 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥389.7m (up 40% from 1Q 2020). Net income: CN¥1.63m (up CN¥15.8m from 1Q 2020). Profit margin: 0.4% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Mar 15New 90-day low: CN¥12.64The company is down 29% from a price of CN¥17.76 on 15 December 2020. Underperformed the Chinese market, which is flat over the last 90 days. Lagged the Biotechs industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Jan 28New 90-day low: CN¥12.66The company is down 36% from its price of CN¥19.93 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.53 per share.
Valuation Update With 7 Day Price Move • Dec 24Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to CN¥14.46, the stock is trading at a trailing P/E ratio of 51.2x, down from the previous P/E ratio of 62.9x. This compares to an average P/E of 63x in the Biotechs industry in China. Total returns to shareholders over the past year are 8.9%.
Is New 90 Day High Low • Dec 24New 90-day low: CN¥14.46The company is down 31% from its price of CN¥20.99 on 25 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.55 per share.
Is New 90 Day High Low • Nov 11New 90-day low: CN¥18.29The company is down 4.0% from its price of CN¥19.06 on 13 August 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥13.16 per share.
Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥141.1m, up 8.5% from the prior year. Total revenue was CN¥1.44b over the last 12 months, up 8.5% from the prior year.
お知らせ • Aug 13Quantum Hi-Tech (China) Biological Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020Quantum Hi-Tech (China) Biological Co., Ltd. announced that they will report first half, 2020 results on Aug 28, 2020
